Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab

Breast cancer related lymphedema (BCRL) is frequent but strategies for an individualized risk assessment are lacking. We aimed to define whether tumor-specific pathological features, coupled with clinical and therapeutic data, could help identify patients at risk. Data from 368 patients with node-positive breast cancers were retrospectively collected, including 75 patients with BCRL (0.4–25.6 years follow-up). BCRL was assessed during the standard follow-up oncology visits using the circumferential measurement. Clinicopathologic and therapeutic factors associated with BCRL were integrated into a Cox proportional hazards regression model. Lymphovascular invasion (LVI) was more common in BCRL patients (n = 33, 44% vs. n = 85, 29%, p = 0.01), akin extra nodal extension (ENE) of the metastasis (n = 57, 76% vs. n = 180, 61%, p = 0.02). Sentinel lymph node excision without axillary dissection and extra-axillary radiotherapy were BCRL-unrelated. A higher number of BCRL-positive patients were treated with taxane-based chemotherapy with or without trastuzumab, compared to BCRL-negative patients (p < 0.01). Treatment with trastuzumab and/or taxanes, adjusted for systemic infections, laterality, therapy, and pathological features (i.e., LVI and ENE), had a significant impact in BCRL-free survival (p < 0.01). This work offers new insights on BCRL risk stratification, where the integration of clinical, therapeutic, and tumor-specific pathological data suggests a possible role of anti-human epidermal growth factor receptor 2 (HER2) therapy in BCRL pathogenesis.

[1]  M. Invernizzi,et al.  Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management. , 2019, Breast.

[2]  V. Vaira,et al.  Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability , 2018, JNCI cancer spectrum.

[3]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Cuzick,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Invernizzi,et al.  Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up , 2018, BMC Cancer.

[6]  A. Taghian,et al.  Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. , 2018, Gland surgery.

[7]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[8]  Y. Shu,et al.  Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema , 2017, Anti-cancer drugs.

[9]  S. Bosari,et al.  HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists , 2016, World journal of gastroenterology.

[10]  Gary H Lyman,et al.  American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Abdolvahab Khademi,et al.  Applied Univariate, Bivariate, and Multivariate Statistics , 2016 .

[12]  J. Taeymans,et al.  Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis , 2016, Breast Cancer Research and Treatment.

[13]  C. Beurskens,et al.  Measurement Properties of Instruments for Measuring of Lymphedema: Systematic Review , 2016, Physical Therapy.

[14]  R. Franco,et al.  The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations , 2015, PloS one.

[15]  A. Mafra da Costa,et al.  Risk Factors for Arm Lymphedema in a Cohort of Breast Cancer Patients Followed up for 10 Years , 2015, Breast Care.

[16]  M. Harries,et al.  Adjuvant taxanes and the development of breast cancer‐related arm lymphoedema , 2015, The British journal of surgery.

[17]  Cynthia L. Miller,et al.  Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort , 2015, Breast Cancer Research and Treatment.

[18]  L. Ward,et al.  Lymphedema following taxane-based chemotherapy in women with early breast cancer. , 2014, Lymphatic research and biology.

[19]  I. Jatoi,et al.  A historical account of breast cancer surgery: beware of local recurrence but be not radical. , 2014, Future oncology.

[20]  W. Wells,et al.  Personalized therapy for breast cancer , 2014, Clinical genetics.

[21]  M. Morrow,et al.  The Extent of Extracapsular Extension May Influence the Need for Axillary Lymph Node Dissection in Patients with T1–T2 Breast Cancer , 2014, Annals of Surgical Oncology.

[22]  Cynthia L. Miller,et al.  Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer , 2013, Breast Cancer Research and Treatment.

[23]  M. Detmar,et al.  Activation of the epidermal growth factor receptor promotes lymphangiogenesis in the skin. , 2013, Journal of dermatological science.

[24]  X. Pivot,et al.  Is extracapsular tumour spread a prognostic factor in patients with early breast cancer? , 2013, International Journal of Clinical Oncology.

[25]  B. Newman,et al.  Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. , 2013, The Lancet. Oncology.

[26]  Y. Borthwick,et al.  Reliability and validity of the figure-of-eight method of measuring hand size in patients with breast cancer-related lymphoedema. , 2013, European journal of cancer care.

[27]  M. Morrow,et al.  Morbidity of Sentinel Node Biopsy: Relationship Between Number of Excised Lymph Nodes and Patient Perceptions of Lymphedema , 2011, Annals of Surgical Oncology.

[28]  M. Dodd,et al.  Comparison of diagnostic accuracy of clinical measures of breast cancer-related lymphedema: area under the curve. , 2011, Archives of physical medicine and rehabilitation.

[29]  M. Gnant,et al.  HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  G. Sakorafas,et al.  Breast cancer surgery: an historical narrative. Part III. From the sunset of the 19th to the dawn of the 21st century. , 2010, European journal of cancer care.

[31]  L. Snetselaar,et al.  The Risk of Developing Arm Lymphedema Among Breast Cancer Survivors: A Meta-Analysis of Treatment Factors , 2009, Annals of Surgical Oncology.

[32]  R. Gelber,et al.  Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  David W. Hosmer,et al.  Applied Survival Analysis: Regression Modeling of Time-to-Event Data , 2008 .

[34]  J Jamart,et al.  Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. , 2007, Lymphology.

[35]  Charles E McCulloch,et al.  Relaxing the rule of ten events per variable in logistic and Cox regression. , 2007, American journal of epidemiology.

[36]  E. Wight,et al.  Morbidity of Sentinel Lymph Node Biopsy (SLN) Alone Versus SLN and Completion Axillary Lymph Node Dissection After Breast Cancer Surgery: A Prospective Swiss Multicenter Study on 659 Patients , 2007, Annals of surgery.

[37]  R W Blamey,et al.  Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. , 2006, European journal of cancer.

[38]  M. Bonetti,et al.  Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Andreas Shamiyeh,et al.  Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma , 2000, Cancer.

[40]  P. Mortimer,et al.  The pathophysiology of lymphedema , 1998, Cancer.

[41]  S. Aamdal,et al.  Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[43]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[44]  P. Rosen.  Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. , 1983, Pathology annual.